UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 6-K
____________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2019
Commission File Number: 001-38177
____________________
Clementia Pharmaceuticals Inc.
(Translation of registrant’s name into English)
____________________
1000 de la Gauchetière West, Suite 1200, Montreal, Quebec, H3B 4W5, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
| | | |
| Form 20-F [ X ] | Form 40-F [ ] | |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS FURNISHED AS PART OF THIS FORM 6-K
A Notice of Special Meeting of Shareholders and Management Information Circular
Form of Proxy for Registered Shareholders
A Letter of Transmittal
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| | Clementia Pharmaceuticals Inc. |
| | (Registrant) |
| | | |
| Date: March 13, 2019 | By: | /s/ Steve Forte |
| | |
| | | Steve Forte |
| | | Chief Financial Officer |
